75279-60-6 Usage
Uses
Used in Pharmaceutical Industry:
(6-Chloro-pyridin-2-yl)-acetonitrile is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of novel drug molecules with potential therapeutic effects.
Used in Agrochemical Industry:
In the agrochemical sector, (6-Chloro-pyridin-2-yl)-acetonitrile serves as a crucial component in the creation of agrochemicals, playing a significant role in the formulation of pesticides and other crop protection agents to enhance agricultural productivity.
Used in Organic Compounds Synthesis:
(6-Chloro-pyridin-2-yl)-acetonitrile is utilized as a building block in the synthesis of a wide range of organic compounds, contributing to the advancement of organic chemistry and the discovery of new chemical entities with diverse applications.
Used in Research and Development Laboratories:
As a valuable intermediate, (6-Chloro-pyridin-2-yl)-acetonitrile is employed in research and development laboratories for the exploration of new chemical reactions and the synthesis of innovative compounds for various applications.
Used in Material Science and Nanotechnology:
(6-Chloro-pyridin-2-yl)-acetonitrile holds potential applications in the field of material science and nanotechnology, where it can be integrated into the design and fabrication of new materials with unique properties for use in various high-tech applications.
Check Digit Verification of cas no
The CAS Registry Mumber 75279-60-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,5,2,7 and 9 respectively; the second part has 2 digits, 6 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 75279-60:
(7*7)+(6*5)+(5*2)+(4*7)+(3*9)+(2*6)+(1*0)=156
156 % 10 = 6
So 75279-60-6 is a valid CAS Registry Number.
InChI:InChI=1/C7H5ClN2/c8-7-3-1-2-6(10-7)4-5-9/h1-3H,4H2
75279-60-6Relevant academic research and scientific papers
PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS
-
Page/Page column 78; 82; 159, (2021/04/10)
The present invention relates to novel compounds of formula (I) and pharmaceutical compositions containing these compounds. The compounds provided herein can act as prostaglandin E2 (PGE2) EP4 receptor antagonists, which renders them highly advantageous for use in therapy, particularly in the treatment or prevention of cancer, a neovascular eye disease, inflammatory pain, or an inflammatory disease, such as, e.g., multiple sclerosis, rheumatoid arthritis or endometriosis.
HETEROCYCLIC COMPOUND
-
Paragraph 0676, (2015/01/18)
The present invention provides an agent for the prophylaxis or treatment of autoimmune diseases (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus etc.) and the like, which has a superior Tyk2 inhibitory action. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.
SEPIAPTERIN REDUCTASE INHIBITORS FOR THE TREATMENT OF PAIN
-
, (2011/05/05)
Disclosed herein are small molecule heterocyclic inhibitors of sepiapterin reductase (SPR), and pro-drugs and pharmaceutically acceptable salts thereof. The Also featured are pharmaceutical compositions of the compounds and uses of these compounds for the treatment or prevention of pain (e.g., inflammatory pain, nociceptive pain, functional pain, and neuropathic pain)
Facile cyanomethylation of bromopyridines by nucleophilic substitution with lithioacetonitrile
Skerlj,Bogucki,Bridger
, p. 1488 - 1490 (2007/10/03)
Substituted bromopyridines undergo facile nucleophilic substitution with lithioacetonitrile under mild conditions to afford the corresponding cyanomethylated products.
